Literature DB >> 2594602

Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.

H D McIntyre1, D P Cameron, S M Urquhart, W E Davies.   

Abstract

A 16 year old male developed symptomatic hypercalcaemia of immobilization on day 47 following a diving accident which had resulted in incomplete C4 tetraplegia. Following initial reduction in serum calcium with salmon calcitonin 100 U/day, symptomatic hypercalcaemia recurred. A single dose of 30 mg pamidronate sodium, given intravenously, caused serum calcium to fall within 48 hours. Initial mild, asymptomatic hypocalcaemia was followed by a return to sustained normocalcaemia. No major adverse reaction was encountered, and if further clinical experience confirms its efficacy, pamidronate sodium will warrant consideration as first-line therapy for immobilization hypercalcaemia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2594602      PMCID: PMC2429267          DOI: 10.1136/pgmj.65.762.244

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

1.  Immobilization hypercalcemia following spinal cord injury.

Authors:  F M Maynard
Journal:  Arch Phys Med Rehabil       Date:  1986-01       Impact factor: 3.966

2.  Quantitative histological data on disuse osteoporosis: comparison with biological data.

Authors:  P Minaire; P Neunier; C Edouard; J Bernard; P Courpron; J Bourret
Journal:  Calcif Tissue Res       Date:  1974

3.  Immobilisation hypercalcaemia in adults and treatment with clodronate.

Authors:  A J Yates; T H Jones; K I Mundy; R V Hague; C B Brown; D Guilland-Cumming; J A Kanis
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-27

4.  Disodium etidronate in hypercalcaemia due to immobilisation.

Authors:  E Hägg; M Eklund; O Tørring
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-25

5.  Immobilization hypercalcemia in acute spinal cord injury treated with etidronate.

Authors:  G J Merli; G E McElwain; A G Adler; J H Martin; J D Roberts; B Schnall; J F Ditunno
Journal:  Arch Intern Med       Date:  1984-06

6.  Calcium homeostasis in immobilization: an example of resorptive hypercalciuria.

Authors:  A F Stewart; M Adler; C M Byers; G V Segre; A E Broadus
Journal:  N Engl J Med       Date:  1982-05-13       Impact factor: 91.245

7.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

Authors:  P M Boonekamp; L J van der Wee-Pals; M M van Wijk-van Lennep; C W Thesing; O L Bijvoet
Journal:  Bone Miner       Date:  1986-02

8.  Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.

Authors:  H I Harinck; O L Bijvoet; H J Blanksma; P J Dahlinghaus-Nienhuys
Journal:  Clin Orthop Relat Res       Date:  1987-04       Impact factor: 4.176

9.  Calcitonin therapy in prolonged immobilization hypercalcemia.

Authors:  D E Carey; L G Raisz
Journal:  Arch Phys Med Rehabil       Date:  1985-09       Impact factor: 3.966

  9 in total
  8 in total

1.  Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.

Authors:  S J Gallacher; S H Ralston; F J Dryburgh; F C Logue; B F Allam; B F Boyce; I T Boyle
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

Review 2.  Biphosphonates.

Authors:  J Allgrove
Journal:  Arch Dis Child       Date:  1997-01       Impact factor: 3.791

Review 3.  Medical management of hypercalcaemia.

Authors:  S H Ralston
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 4.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

5.  Pamidronate treatment of pediatric fracture patients on chronic steroid therapy.

Authors:  Philip D Acott; Jaime A Wong; Bianca A Lang; John F S Crocker
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

6.  Denosumab for treatment of immobilization-related hypercalcaemia in a patient with advanced renal failure.

Authors:  Esther de Beus; Walther H Boer
Journal:  Clin Kidney J       Date:  2012-10-07

Review 7.  At the bottom of the differential diagnosis list: unusual causes of pediatric hypertension.

Authors:  Matthew M Grinsell; Victoria F Norwood
Journal:  Pediatr Nephrol       Date:  2008-03-05       Impact factor: 3.714

8.  Unmasking of primary hyperparathyroidism by Vitamin D therapy.

Authors:  S Bala; B Shah; P Rajput; P Rao
Journal:  Indian J Nephrol       Date:  2015 Nov-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.